Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Age-Related Neovascular Macular Degeneration”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT00305630
What this trial is testing

Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)

Who this might be right for
Choroidal NeovascularizationAge-Related Macular Degeneration
Johns Hopkins University 100
Not applicableStudy completedNCT05066685
What this trial is testing

Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 18,457
Early research (Phase 1)Study completedNCT00320775
What this trial is testing

Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD

Who this might be right for
Macular Degeneration
Regeneron Pharmaceuticals 51
Not applicableStudy completedNCT05110209
What this trial is testing

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 331,541
Large-scale testing (Phase 3)Ended earlyNCT04757636
What this trial is testing

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration
Opthea Limited 998
Not applicableUnknownNCT04907409
What this trial is testing

Home OCT Fluid Visualization Agreement Study

Who this might be right for
Neovascular Age-related Macular Degeneration
Notal Vision Inc. 120
Early research (Phase 1)Not Yet RecruitingNCT06623279
What this trial is testing

Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
HuidaGene Therapeutics Co., Ltd. 15
Post-approval studies (Phase 4)Study completedNCT01127360
What this trial is testing

LUCAS (Lucentis Compared to Avastin Study)

Who this might be right for
Exudative Age-related Macular Degeneration
Oslo University Hospital 420
Testing effectiveness (Phase 2)Study completedNCT02507388
What this trial is testing

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Alcon Research 51
Post-approval studies (Phase 4)Study completedNCT02305238
What this trial is testing

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

Who this might be right for
Wet Macular Degeneration
Bayer 288
Post-approval studies (Phase 4)Study completedNCT04679935
What this trial is testing

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 52
Not applicableStudy completedNCT00460408
What this trial is testing

Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

Who this might be right for
Macular Degeneration
Pfizer 501
Testing effectiveness (Phase 2)Study completedNCT01134055
What this trial is testing

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
GlaxoSmithKline 510
Testing effectiveness (Phase 2)Study completedNCT00344227
What this trial is testing

Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)

Who this might be right for
Neovascular Age-Related Macular Degeneration
University of Miami 40
Not applicableLooking for participantsNCT07308639
What this trial is testing

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
Bayer 50,000
Not applicableEnded earlyNCT04935411
What this trial is testing

Russian Registry of Patients With nAMD

Who this might be right for
Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals 2,665
Early research (Phase 1)Study completedNCT04989699
What this trial is testing

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. 21
Large-scale testing (Phase 3)Study completedNCT04857177
What this trial is testing

Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration

Who this might be right for
Neovascular(Wet) Age Related Macular Degeneration
Chong Kun Dang Pharmaceutical 312
Not applicableActive Not RecruitingNCT06717139
What this trial is testing

Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD

Who this might be right for
Retinal DiseasesMacular DegenerationNeovascular (Wet) Age-Related Macular Degeneration
St. Erik Eye Hospital 220
Large-scale testing (Phase 3)Looking for participantsNCT07064759
What this trial is testing

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics 480
Next Page